Back to Results
First PageMeta Content
Intensive care medicine / Hypertension / Bronchopulmonary dysplasia / Nitric oxide / Pulmonary hypertension / Preterm birth / Extracorporeal membrane oxygenation / Medicine / Health / Chemistry


IKARIA® COMPLETES PATIENT ENROLLMENT IN PIVOTAL PHASE III TRIAL FOR BRONCHOPULMONARY DYSPLASIA -- Enrollment Concludes Ahead of Schedule -- Hampton, NJ – February 27, 2012 – Ikaria, Inc., a critical care company foc
Add to Reading List

Document Date: 2012-04-04 15:36:14

Open Document

File Size: 95,82 KB

Share Result on Facebook

City

Madison / Hampton / /

Company

Ikaria Inc. / /

Country

Puerto Rico / Japan / Canada / Australia / Mexico / /

Event

FDA Phase / /

Facility

Port Allen / /

IndustryTerm

drug-device combination product / drug product / treatment of hypoxic respiratory failure / manufacturing facilities / gas mixtures / treatment for Hepatorenal Syndrome / /

MedicalCondition

bronchopulmonary dysplasia / FOR BRONCHOPULMONARY DYSPLASIA / pulmonary blood vessels / pulmonary arterial hypertension / chronic obstructive pulmonary disease / respiratory distress syndrome / airway inflammation / pulmonary hypertension / subsequent congestive heart failure / chronic lung disease / pulmonary vasculature / hypoxic respiratory failure / Methemoglobinemia / acute myocardial infarction / /

MedicalTreatment

positive-pressure ventilation / innovative therapies / extracorporeal membrane oxygenation / mechanical ventilation / /

Organization

National Institute of Health / U.S. Food and Drug Administration / /

Person

Daniel Tassé / Douglas A. Greene / /

Position

Executive Vice President of Research & Development / Chairman and CEO / /

Product

INOMAX / BRONCHOPULMONARY DYSPLASIA / /

ProvinceOrState

New Jersey / Wisconsin / /

Technology

drug-delivery system / /

URL

www.ikaria.com / www.inomax.com / /

SocialTag